Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bromocriptine in tardive dyskinesia.

J E Häggström, U Andersson, L M Gunne

    Pharmacopsychiatria
    |September 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Bromocriptine showed mixed effects on tardive dyskinesia in schizophrenic patients. While it did not affect symptoms during neuroleptic treatment, it later improved or worsened dyskinesia after neuroleptic withdrawal.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Sexual harassment among employees and students at a large Swedish university: who are exposed, to what, by whom and where - a cross-sectional prevalence study.

    BMC public health·2022
    Same author

    Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial.

    Journal of internal medicine·2017
    Same author

    The haptoglobin beta subunit sequesters HMGB1 toxicity in sterile and infectious inflammation.

    Journal of internal medicine·2017
    Same author

    The functions of HMGB1 depend on molecular localization and post-translational modifications.

    Journal of internal medicine·2014
    Same author

    D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial.

    Journal of thrombosis and haemostasis : JTH·2014
    Same author

    HMGB1 mediates splenomegaly and expansion of splenic CD11b+ Ly-6C(high) inflammatory monocytes in murine sepsis survivors.

    Journal of internal medicine·2013

    Area of Science:

    • Neuroscience
    • Psychiatry
    • Pharmacology

    Background:

    • Tardive dyskinesia is a potential side effect of neuroleptic treatment.
    • The dopamine agonist bromocriptine's effect on tardive dyskinesia is not fully understood.

    Purpose of the Study:

    • To investigate the efficacy of bromocriptine in treating tardive dyskinesia in patients with schizophrenia.
    • To assess bromocriptine's impact on psychotic symptoms during and after neuroleptic treatment.

    Main Methods:

    • A two-period, 8-week study involving six patients (five schizophrenic, one alcoholic) with tardive dyskinesia.
    • Bromocriptine was administered during neuroleptic treatment and again after a 3-week neuroleptic washout period.

    Main Results:

    Related Experiment Videos

  • Bromocriptine had no significant effect on tardive dyskinesia during concurrent neuroleptic treatment.
  • After neuroleptic withdrawal, bromocriptine led to amelioration of dyskinesia in three patients and aggravation in two.
  • Schizophrenic patients experienced psychotic symptom deterioration during bromocriptine treatment post-neuroleptic withdrawal, which resolved upon discontinuation.

    • Conclusions:

    • Bromocriptine's effect on tardive dyskinesia appears dependent on the presence of neuroleptic medication.
    • Bromocriptine may exacerbate psychotic symptoms in schizophrenic patients when neuroleptics are withdrawn.